{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:58:51Z","timestamp":1794848331946,"version":"4.9.1"},"reference-count":35,"publisher":"Informa UK Limited","issue":"38","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,12,4]]},"DOI":"10.1080\/14796694.2024.2402680","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T12:03:36Z","timestamp":1728561816000},"page":"3065-3075","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II\u00a0trial"],"prefix":"10.1080","volume":"20","author":[{"given":"Ehab L","family":"Atallah","sequence":"first","affiliation":[{"name":"Medical College of Wisconsin","place":["Milwaukee, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Mauro","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe Y","family":"Levy","sequence":"additional","affiliation":[{"name":"Texas Oncology, US Oncology Network","place":["Dallas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Koller","sequence":"additional","affiliation":[{"name":"City of Hope","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Yang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dramane","family":"Laine","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sabo","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennan","family":"Gu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E","family":"Cortes","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center","place":["Augusta, USA"]},{"name":"Augusta University","place":["Augusta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"e_1_3_8_3_1","volume-title":"SOHO2022.","author":"Sasaki K","unstructured":"Sasaki K, Mauro MJ, Levy MY, et al. ASC2ESCALATE trial in progress: a Phase II, single-arm, dose-escalation study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase previously treated with 1 prior tyrosine kinase inhibitor. Presented at: SOHO2022. Houston, TX. Poster CML-433, September 28-October 1."},{"key":"e_1_3_8_4_1","volume-title":"SOHO2023.","author":"Atallah EL","unstructured":"Atallah EL, Mauro MJ, Sasaki K, et al. ASC2ESCALATE: a US, Phase II, single-arm, dose-escalation study of asciminib monotherapy in second-line and first-line treatment of patients with chronic myeloid leukemia in chronic phase. Presented at: SOHO2023. Houston, TX, and virtual. Poster CML-573, September 6-9."},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31823dec8d"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24275"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13524"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458"},{"issue":"7","key":"e_1_3_8_16_1","first-page":"421","article-title":"The \u201chit hard and hit early\u201d approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer Network clinical practice guidelines for routine practice","volume":"11","author":"Akard LP","year":"2013","unstructured":"Akard LP, Albitar M, Hill CE, Pinilla-Ibarz J. The \u201chit hard and hit early\u201d approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer Network clinical practice guidelines for routine practice. Clin Adv Hematol Oncol. 2013;11(7):421\u2013432.","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_3_8_17_1","volume-title":"25th European Hematology Association Annual Congress (EHA25 Virtual).","author":"Cortes J","year":"2020","unstructured":"Cortes J, Brummendorf TH, Goh YT, et al. Bosutinib for chronic phase chronic myeloid leukemia after imatinib failure: >8-year update of a Phase I\/II study. Presented at: 25th European Hematology Association Annual Congress (EHA25 Virtual). 11\u201314 June 2020."},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2018.11.005"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01040"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984"},{"key":"e_1_3_8_22_1","volume-title":"2022 American Society of Clinical Oncology Annual Meeting.","author":"Rea D","year":"2022","unstructured":"Rea D, Mauro MJ, Hochhaus A, et al. Efficacy and safety results from ASCEMBL, a Phase III study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: week 96 update. Presented at: 2022 American Society of Clinical Oncology Annual Meeting. Chicago, IL; 3\u20137 June 2022."},{"key":"e_1_3_8_23_1","volume-title":"European Hematology Association 2022 Congress.","author":"Rea D","year":"2022","unstructured":"Rea D, Hochhaus A, Mauro MJ, et al. Efficacy and safety results from ASCEMBL, a Phase III study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: week 96 update. Presented at: European Hematology Association 2022 Congress. Vienna, Austria, and virtual; 17\u201320 October 2022."},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01829-9"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01662-3"},{"key":"e_1_3_8_26_1","volume-title":"Summary of product characteristics.","author":"Scemblix (asciminib)","year":"2022","unstructured":"Scemblix (asciminib). Summary of product characteristics. Dublin, Ireland: Novartis Europharm Limited; 2022."},{"key":"e_1_3_8_27_1","volume-title":"Prescribing information.","author":"Scemblix (asciminib)","year":"2021","unstructured":"Scemblix (asciminib). Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021."},{"key":"e_1_3_8_28_1","unstructured":"Novartis [Internet]. Novartis Scemblix\u00ae with novel mechanism of action approved by the European Commission for adult patients with chronic myeloid leukemia. 29 August 2022 [cited 2023 Sep 29]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-scemblix-novel-mechanism-action-approved-european-commission-adult-patients-chronic-myeloid-leukemia"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01055-9"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24066"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14829"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172583"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01860-w"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163078"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152561"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167044"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2402680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:38:00Z","timestamp":1778744280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2402680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":35,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2024,12,4]]}},"alternative-id":["10.1080\/14796694.2024.2402680"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2402680","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}